1. Home
  2. DOV vs BIIB Comparison

DOV vs BIIB Comparison

Compare DOV & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dover Corporation

DOV

Dover Corporation

HOLD

Current Price

$196.08

Market Cap

25.1B

Sector

Industrials

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$170.14

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOV
BIIB
Founded
1947
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.1B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
DOV
BIIB
Price
$196.08
$170.14
Analyst Decision
Buy
Buy
Analyst Count
11
22
Target Price
$213.18
$177.40
AVG Volume (30 Days)
1.1M
2.0M
Earning Date
01-29-2026
10-30-2025
Dividend Yield
1.04%
N/A
EPS Growth
45.52
N/A
EPS
16.27
10.97
Revenue
$7,923,358,000.00
$10,065,900,000.00
Revenue This Year
$5.23
$3.61
Revenue Next Year
$5.52
N/A
P/E Ratio
$12.24
$15.86
Revenue Growth
2.62
4.77
52 Week Low
$143.04
$110.04
52 Week High
$222.31
$185.17

Technical Indicators

Market Signals
Indicator
DOV
BIIB
Relative Strength Index (RSI) 63.86 48.03
Support Level $189.45 $169.24
Resistance Level $203.69 $175.94
Average True Range (ATR) 3.60 4.92
MACD 0.81 -1.89
Stochastic Oscillator 64.94 5.98

Price Performance

Historical Comparison
DOV
BIIB

About DOV Dover Corporation

Founded in 1955 by George Ohrstrom, Dover has become an industrial behemoth through the acquisition of dozens of esteemed brands. The company is organized into five segments through which it designs and manufactures highly engineered components, such as vehicle repair, factory automation, welding, aerospace, fuel dispensing, printing, liquid handling, refrigeration, and can-making equipment. It has operations around the globe but generates over half of its revenue in the United States.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: